Extended Data Fig. 3: Basal signalling in CD4 T cells in DS.
From: Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+ B cells
(A) Basal STAT3 phosphorylation in CD4 T cell subsets from HCs (n = 13), individuals with DS (n = 19), and adults with DS and COVID-19 (n = 5) expressed as Log2FC over the mean HCs per subset. Significance assessed by one-way ANOVA with Tukey’s post-hoc analysis, ns denotes p > 0.05, *p ≤ 0.05; **p ≤ 0.005, ***p ≤ 0.0005. Whiskers denote min and max values, bounds of box denote Q1–Q3, and centre bar denotes mean. (B) Basal STAT5 phosphorylation in CD4 T cell subsets from individuals with DS (n = 14) and age-matched controls (n = 10), expressed as Log2FC over the mean HCs per subset. (C-D) STAT3 phosphorylation in CD4 T cell subsets expressed as Log2FC over the mean mock-treated HCs per subset after ex vivo whole blood treatment for 4 h with (C) Tofacitinib (500nM) (n = 6 HC, n = 7 DS), (D) Tocilizumab (50 μg ml−1) (n = 4 HC, n = 7 DS). (E) Surface expression of IL-6R in CD4 T cells from adults with DS (n = 3) and age-matched HCs (n = 3). (F) STAT3 phosphorylation in CD4 T cell subsets induced by stimulation of whole blood with recombinant IL-6 (50 ng ml−1) for 15 min, expressed as Log2FC over the mean mock-treated HCs (n = 2 HC, n = 4 DS). Box plots denote min and max values for HCs, error bars indicate SD and centre denotes mean for DS. (C-E) Error bars denote SD. (B-F) Significance assessed by two-tailed paired t tests, ns denotes p > 0.05, *p ≤ 0.05; **p ≤ 0.005, ***p ≤ 0.0005.
